PierianDx Announces Expanded Partnership with Illumina to Support Cancer Genomic Reporting in Global Markets
1.12.2020 19:00:00 EET | Business Wire | Press release
PierianDx, the leading clinical genomics informatics company, today announced an expanded partnership with Illumina to enable PierianDx genomic reporting solutions for use with AmpliSeq™ for Illumina ® Focus Panel, AmpliSeq™ for Illumina ® Myeloid Panel and the TruSight™ Hereditary Cancer Panel. Adding these panels expands the existing relationship between Illumina and PierianDx, which currently covers use of the PierianDx platform to support genomic reporting in key global markets for the TruSight Oncology 500 portfolio.
Performing a comprehensive NGS test and delivering an accompanying genomic report were once only accomplished via a send-out test to a commercial lab. However, in performing tests as send-outs, healthcare organizations relinquish control over samples, turnaround time, and quality. The PierianDx platform enables healthcare organizations to accelerate their precision medicine programs by empowering them to create accurate, timely, and comprehensive clinical genomic reports in-house.
Illumina’s Senior Vice President and Chief Medical Officer Dr. Phil Febbo said: “PierianDx has demonstrated its commitment to best-in-class variant reporting solutions. We are excited to expand our partnership to cover the AmpliSeq™ suite of panels which are optimized for clinical cancer research.”
PierianDx develops Clinical Genomics Workspace™, which consists of intuitive software and a robust clinical knowledgebase which transforms unstructured variant information into a highly structured and usable clinical genomic report. In use by academic medical centers, cancer centers, reference laboratories, and healthcare organizations worldwide, it helps users accurately and rapidly classify and interpret variants to produce a physician-ready report.
Lincoln Nadauld, Vice President and Chief of Precision Medicine and Genomics, Intermountain Healthcare, explains, “Our partnership with PierianDx has enabled us to advance our precision medicine program by enhancing the classification of variants, accelerating the identification of targeted therapies, and expanding clinical trial opportunities for our patients.”
About PierianDx
Founded in 2014 out of Washington University in St. Louis, PierianDx is focused on advancing cancer diagnostics and making targeted therapeutics more accessible to healthcare systems, laboratories, and patients worldwide. Its industry-leading clinical genomics technologies, CAP and CLIA accredited laboratory, IVD-ready knowledgebase and reporting solution, and expertise deliver the most integrated, trusted, and collaborative approach across the clinical care spectrum. From genomic sequencing and biomedical informatics in the laboratory to reporting and decision support at the patient’s bedside, PierianDx drives the adoption of genomics in clinical care and accelerates the fight against somatic cancer and hereditary germline diseases. www.pieriandx.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201201005427/en/
Contact information
Lisa Owen
lowen@pieriandx.com
Cell : 206-851-6246
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Leblon Delienne Joins LEXON at BOW to Expand Its Global Reach8.9.2026 15:36:00 EEST | Press release
BOW (Brands of Wonder), the international brand group behind French design brand LEXON, today announced the acquisition of Leblon Delienne, the French sculpture atelier known for transforming pop culture icons into collectible art and design objects. The move pairs the atelier’s distinctive French craftsmanship and licensed collections with BOW’s international reach and digital expertise. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260908641342/en/ Leblon Delienne Joins LEXON at BOW Juliette de Blegiers, who acquired the company in 2018, will remain a minority shareholder in Leblon Delienne and continue working alongside BOW founder Boris Brault and the atelier’s teams. For more than 40 years, Leblon Delienne has brought iconic characters to life through sculptures, figurines, furniture, and art and design objects, primarily in limited, numbered editions. Its licensed collections feature characters from Disney, Warner Bro
Visa Brings Onchain Lending into Everyday Payments8.9.2026 15:00:00 EEST | Press release
Today, Visa (NYSE: V) announced a new approach to onchain credit designed to help stablecoin-linked card programs and fintechs access working capital using onchain lending infrastructure and Visa data. Onchain lending has emerged as one of the fastest-growing segments of digital finance. According to the Visa Onchain Analytics Dashboard, since 2020, more than $694 billion in stablecoin-denominated loans have been sent through onchain lending protocols, creating a global credit market that operates 24/7. Yet much of that activity remains concentrated within crypto markets and hasn’t meaningfully supported the businesses and payment experiences people use every day. Visa is helping bridge that gap by combining VisaNet settlement data with onchain credit infrastructure. This information can help lenders better understand how a program is operating, making it easier to evaluate financing opportunities that fit their needs and extend capital to support their goals. "Stablecoins are not only
Samsung Electronics and ASML Expand Strategic Collaboration for Next-Generation Semiconductor Manufacturing8.9.2026 14:51:00 EEST | Press release
Samsung Electronics and ASML today announced an expansion of their long-standing strategic partnership, deepening collaboration on High NA EUV lithography and advanced semiconductor manufacturing technologies that will help drive the next generation of innovation in the AI era. Building on years of successful cooperation, the companies will work together to accelerate the development and deployment of technologies that support the increasing performance and efficiency requirements of advanced semiconductor manufacturing. Samsung will join the industry initiative to advance next-generation 12-inch photomask technology for future manufacturing. The semiconductor industry has relied on the 6-inch photomask format for decades. With High NA EUV, the transition to larger, 12-inch masks is expected to further increase fab productivity, lower chipmaking costs and remove stitching constraints. It will enable advanced chip manufacturers to fully leverage the advantages of High NA EUV, making fut
Hovione Appoints Stefan Doboczky as Chief Executive Officer8.9.2026 14:16:00 EEST | Press release
Hovione Holding AG today announced the appointment of Stefan Doboczky as Chief Executive Officer (CEO), effective April 1, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260908358544/en/ Stefan Doboczky, Chief Executive Officer of Hovione. Photo credit: Karl Michalski. Stefan Doboczky has served as Chairman of the Board of Directors of Hovione Holding AG since 2024, where he has been instrumental in shaping the company’s strategy and vision. He will step down as Chairman on assuming the role of Chief Executive Officer. Founded in 1959, Hovione is a family-owned pharmaceutical technology and services group serving the industry worldwide, with more than 2,600 employees, four FDA-inspected production and R&D sites in Europe, the United States and China, and internationally recognized technology leadership in spray drying and continuous tableting. The appointment marks a return to the pharmaceutical industry for Stefan Dob
Hirect to Showcase In-House Developed 6,000 HP Electric Locomotive Propulsion System and Indian Railways Contract at InnoTrans 20268.9.2026 14:09:00 EEST | Press release
Hirect (NSE: HIRECT), a premier manufacturer of heavy-duty electrical and power electronic systems for rail network rolling stock, will debut its new 6,000 HP locomotive propulsion system at InnoTrans 2026, Berlin, 22 - 25 September. The company will also announce the first development order for the complete trainset propulsion system, which will deliver the power and traction package for Indian Railways' next-generation Mainline Electric Multiple Unit (MEMU) fleet. Hirect's 6,000 HP electric locomotive propulsion system — designed, engineered and manufactured entirely in-house, including its liquid-cooled IGBT traction inverters/converters and proprietary control software — completed its acceptance regime this year after successfully hauling loaded freight in a WAG-9 locomotive under India's severe duty cycles and demanding thermal operating environment. The qualification opens one of the world's largest locomotive markets to Hirect's complete propulsion package, and establishes a mod
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom